A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice.
A RANKL-derived peptide is making waves in lung cancer research. Japanese scientists took their custom peptide, called MHP1-AcN, and tested it against lung adenocarcinoma in mice. The results: solid tumor suppression, less cell migration, and a direct hit to the RSPO3-LGR4-Wnt signaling pathway.
Anticancer Res
by Ju N, Hayashi H, Chang C et al.
“A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice. Ju N(1), Hayashi H(2), Chang C(1), Nakagami H(2), Morishita R(3), Shimamura M(4)(5). Author information: (1)Department of Gene & Stem Cell Regenerative Therapy, Graduate School of Medicine, The University of Osaka, Suita, Japan. (2)Department of Health Development and Medicine, Graduate School of Medicine, The University of Osaka, Suita, Japan. (3)Department of Clinical Gene Therapy, Graduate School of Medicine, The University of Osaka Suita, Japan. (4)Department of Gene & Stem Cell Regenerative Therapy, Graduate School of Medicine, The University of Osaka, Suita, Japan; shimamuu@cgt.med.osaka-u.ac.jp. (5)Department of Neurology, Graduate School of Medicine, The University of Osaka, Suita, Japan. BACKGROUND/AIM: Despite advances in therapy, lung cancer remains the leading cause of cancer-related mortality. R-spondin (RSPO) 3 and its receptor, leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4), drive tumor progression in a subset of lung adenocarcinomas by potentiating Wnt signaling. In addition to RSPO3, LGR4 is also a receptor for receptor activator of nuclear factor-кB ligand (RANKL). Here, we investigated whether MHP1-AcN, our previously developed RANKL-derived peptide, acts on LGR4 and examined its effects on RSPO3-LGR4 signaling in A549 lung cancer cells. MATERIALS AND METHODS: An A549 xenograft model was established by subcutaneous inoculation in BALB/c nude mice, followed by daily intraperitoneal administration of MHP1-AcN. Tumor growth was assessed by volume and weight. In vitro, the effect of MHP1-AcN on A549 cell proliferation, cytotoxicity, migration, and invasion were evaluated. Molecular interactions and signaling pathways were analyzed using immunoprecipitation and immunoblotting. RESULTS: Intraperitoneal administration of MHP1-AcN significantly reduced tumor volume and weight in the subcutaneous A549 xenograft model. Mechanistically, MHP1-AcN directly interacted with LGR4 and disrupted RSPO3-induced LGR4-IQ motif-containing GTPase activating protein 1 complex formation. MHP1-AcN inhibited A549 cell proliferation without inducing cytotoxicity and suppressed RSPO3-enhaced phosphorylation of LRP6 and accumulation of β-catenin. Furthermore, MHP1-AcN dose-dependently inhibited A549 cell migration and invasion by reducing focal adhesion kinase phosphorylation and disrupting F-actin organization. CONCLUSION: These findings demonstrate MHP1-AcN as a novel LGR4 antagonist that inhibits RSPO3-LGR4-Wnt signaling, tumor growth, and metastatic potential in lung adenocarcinoma, highlighting its potential as a therapeutic agent targeting this pathway. Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.”
Here's why it matters. The RSPO3-LGR4-Wnt axis drives tumor growth in certain lung adenocarcinomas. Until now, blocking this pathway with precision has been tricky. MHP1-AcN, a peptide based on RANKL, steps in as a novel LGR4 antagonist. That means it can bind to LGR4, block RSPO3 activity, and shut down downstream signals that fuel tumor growth and spread.
Key findings, boiled down:
Mice injected with human lung cancer cells and treated with MHP1-AcN grew smaller tumors, both by volume and weight.
The peptide blocked RSPO3-induced complex formation at the molecular level, interfering with signals that drive cell proliferation.
Importantly, MHP1-AcN stopped cancer cells from moving and invading—without killing them outright. It disrupted signals inside the cell (like FAK phosphorylation) and messed with the actin skeleton, making it harder for cells to crawl and metastasize.
No cytotoxicity was observed, suggesting a clean mechanism of action.
This research backs up the promise of peptides as highly targeted tools in oncology and cell signaling studies. The door is wide open for deeper exploration of RSPO3-LGR4-Wnt inhibition, not just in lung cancer but anywhere this pathway gets hijacked.
For researchers interested in the details, MHP1-AcN now joins the growing list of peptides worth a closer look. See more in our peptide research index.
New antagonist peptides like this are fueling innovation—expect more breakthroughs as research ramps up.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.